Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KDR | P35968 | 2/20 | 0.54 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6137351 | 0.90 | RORC (0.50) | ALDH1A1HPGDF2RL3SCN9APTGER1 | |
| SCHEMBL6137028 | 0.85 | RORC (0.59) | ALDH1A1HPGDSCN9AHTTPTGER1 | |
| SCHEMBL5945786 | 0.83 | SCN9A (0.62) | ALDH1A1HPGDSCN9AFGFR1RORC | |
| SCHEMBL6136884 | 0.79 | RORC (0.66) | HPGDHTTPTGER1RORC | |
| SCHEMBL19471865 | 0.75 | RORC (0.56) | ALDH1A1HPGDSMN1; SMN2MAPK1KMT2A | |
| Hydrochloric Acid SCHEMBL6136775 | 0.75 | RORC (0.57) | HPGDSMN1; SMN2HTTPTGER1RORC | |
| Hydrochloric Acid SCHEMBL6136946 | 0.75 | RORC (0.57) | HPGDSMN1; SMN2HTTPTGER1RORC | |
| SCHEMBL6136871 | 0.74 | RORC (0.53) | HPGDSMN1; SMN2KMT2AMEN1KDM4E | |
| SCHEMBL6136970 | 0.73 | HPGD (0.42) | HPGDF2RL3SCN9AKMT2AMEN1 | |
| SCHEMBL6137025 | 0.73 | F2RL3 (0.51) | HPGDF2RL3KMT2AMEN1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050227299-A1 | Fluorescent dyes (AIDA) for solid phase and solution phase screening | AUER MANFRED | 2005-10-13 | — | — | US | disclosed |
| EP-1140856-B1 | FLUORESCENT DYES FOR SOLID PHASE AND SOLUTION PHASE SCREENING | NOVARTIS AG (CH) | 2005-04-27 | — | — | EP | disclosed |
| EP-1140856-A1 | FLUORESCENT DYES FOR SOLID PHASE AND SOLUTION PHASE SCREENING | Novartis AG (CH) | 2001-10-10 | — | — | EP | disclosed |
| US-20010005752-A1 | Fluorescent dyes (AIDA) for solid phase and solution phase screening | AUER MANFRED (AT) | 2001-06-28 | — | — | US | disclosed |
| US-6207831-B1 | A BENZOPYRAZOLE COMPOUND | NOVARTIS AG (CH) | 2001-03-27 | — | — | US | disclosed |
| WO-2000037448-A1 | FLUORESCENT DYES FOR SOLID PHASE AND SOLUTION PHASE SCREENING | NOVARTIS AG (CH) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010005752-A1 | Fluorescent dyes (AIDA) for solid phase and solution phase screening | SLC43A1, CUTA, ANXA1 | ALDH1A1 1296/4885HPGD 4341/4885SMN1; SMN2 1017/4885 |
| US-20050227299-A1 | Fluorescent dyes (AIDA) for solid phase and solution phase screening | SLCO1A2, ABCG2, SLCO1B1 | ALDH1A1 54/4885HPGD 2745/4885SMN1; SMN2 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.